Loading...
Loading...
Healthcare
Executive compensation benchmarks for 34 public companies in the pharmaceutical preparations industry.
$14.3M
34
$163.3M
235:1
Median
$14,272,413
Average
$17,794,137
25th Percentile
$9,525,245
75th Percentile
$17,239,258
Minimum
$107,530
Maximum
$163,293,744
Avg Pay Ratio
235:1
Companies
34
Click any company to see full compensation breakdown
The median pharmaceutical preparations CEO compensation is $14,272,413, based on 34 public companies. The average is $17,794,137. Note that CEO compensation includes salary, bonus, stock awards, option awards, and other compensation.
Matthew Gline of Roivant Sciences Ltd. is the highest paid pharmaceutical preparations CEO, with total compensation of $163,293,744 in FY2024.
The average CEO-to-median-employee pay ratio in the pharmaceutical preparations industry is 235:1. This means the average CEO earns 235 times what the median employee earns.
Data sourced from SEC filings (DEF 14A proxy statements). Last updated: March 1, 2026. Compensation figures are total annual compensation including salary, bonus, stock awards, and other compensation.
Compare CEO compensation across different industries or research specific companies.
| Company | CEO | Total Comp |
|---|---|---|
| Roivant Sciences Ltd. ROIV | Matthew Gline | $163.3M |
| ELI LILLY & Co LLY | David A. Ricks | $29.2M |
| JOHNSON & JOHNSON JNJ | J. Duato | $24.3M |
| AbbVie Inc. ABBV | Richard A. Gonzalez | $24.1M |
| Merck & Co., Inc. MRK | Robert M. Davis | $23.2M |
| ABBOTT LABORATORIES ABT | Robert B. Ford | $22.8M |
| VERTEX PHARMACEUTICALS INC / MA VRTX | Reshma Kewalramani | $21.5M |
| BeOne Medicines Ltd. ONC | John V. Oyler | $20.8M |
| Nuvalent, Inc. NUVL | James R. Porter | $17.3M |
| Organon & Co. OGN | Kevin Ali | $17.1M |
| BridgeBio Pharma, Inc. BBIO | Neil Kumar | $15.6M |
| Jazz Pharmaceuticals plc JAZZ | Bruce C. Cozadd | $15.5M |
| TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA | Richard Francis | $15.5M |
| UNITED THERAPEUTICS Corp UTHR | Martine Rothblatt | $15.4M |
| BIOMARIN PHARMACEUTICAL INC BMRN | Alexander Hardy | $14.9M |
| RHYTHM PHARMACEUTICALS, INC. RYTM | David P. Meeker | $14.7M |
| CYTOKINETICS INC CYTK | Robert I. Blum | $14.4M |
| Avidity Biosciences, Inc. RNA | Sarah Boyce | $14.2M |
| MADRIGAL PHARMACEUTICALS, INC. MDGL | Bill Sibold | $12.2M |
| ALNYLAM PHARMACEUTICALS, INC. ALNY | Yvonne L. Greenstreet | $11.5M |
| INSMED Inc INSM | William | $10.9M |
| IONIS PHARMACEUTICALS INC IONS | Brett P. Monia | $10.7M |
| Axsome Therapeutics, Inc. AXSM | Herriot Tabuteau | $10.4M |
| CORCEPT THERAPEUTICS INC CORT | Joseph K. Belanoff | $9.9M |
| Merus N.V. MRUS | Sven (Bill) Ante Lundberg | $9.7M |
| Protagonist Therapeutics, Inc PTGX | Dinesh V. Patel | $9.5M |
| ARROWHEAD PHARMACEUTICALS, INC. ARWR | Christopher Anzalone | $9.0M |
| PTC THERAPEUTICS, INC. PTCT | Matthew B. Klein | $7.4M |
| REGENERON PHARMACEUTICALS, INC. REGN | Leonard S. Schleifer | $6.8M |
| Viatris Inc VTRS | Doretta Mistras | $6.4M |
| Cogent Biosciences, Inc. COGT | Andrew Robbins | $4.9M |
| Summit Therapeutics Inc. SMMT | Mahkam Zanganeh | $1.2M |
| KAMADA LTD KMDA | Amir London | $684K |
| Abivax S.A. ABVX | Claret Financing | $108K |